uidel Corp. develops, manufactures and markets point-of-care rapid diagnostic tests for the detection and management of a variety of medical conditions and illnesses.
Value
Total number of shares outstanding as of May 8, 2000 24,600,000
Price of each share of common stock on May 8, 2000 $7.0625
Aggregate market value as of May 8, 2000 $173,737,500.00
Performance Record
For year ended March 31, in thousands, except per-share data
1999 1998 1997
Total revenues $51,496 $49,479 $44,722
Net income (loss) $7,661 $1,110 $3,549
Net income (loss) per share $0.32 $0.05 $0.16
Total assets $52,606 $47,782 $42,261
Directors
Richard C.E. Morgan, 56, has been director since May 1990 and chairman since July 1995. In November 1999, he was a co-founder, chairman and CEO of incuVest LLC.
Andre de Bruin, 53, was appointed as president and CEO in June 1998.
John D. Diekman, 57, is a managing director of Bay City Capital, L.L.C., an investment banking company.
George W. Dunbar Jr., 53, is a founding member of iCEO, a service provider of CEO and executive talent for start-up companies. He is the acting president and CEO of CytoTherapeutics, Inc. and StemCells, Inc.
Thomas A. Glaze, 53, co-founded Quidel and has been a director since April 1979. He is president and CEO of Metabolex, Inc.
Margaret G. McGlynn, 40, served as senior vice president of worldwide human health marketing at Merck & Co., Inc.
Mary Lake Polan, 56, has served as the chair of the department of gynecology and obstetrics at Stanford University of Medicine since 1990.
Faye Wattleton, 56, has been president of the Center of Gender Equality since 1995 and president of Mefel Associates since 1985.
Executive Compensation
Officers Cash Compensation
Andre de Bruin, president and CEO $361,286
Charles Cashion, senior vice president, CFO and secretary $80,000
Charles H. Bowden, chief medical officer, vice president of infectious diseases $150,426
Mark E. Paiz, senior vice president of product development and
supply operations $138,590
John D. Tamerius, vice president, autoimmune and complement and GM of
Mountain View operations $174,265
Robin G. Weiner, vice president of clinical development and regulatory affairs $124,969
Significant Stock Ownership
Number of shares Percent
March 31, 2000
Larry N. Feinberg 2,840,000 11.55
All directors and officers as a group (13 persons) 2,400,347 9.32
Other Information
Headquarters: 10165 McKellar Court, San Diego, CA 92121; (858) 552-1100; fax (858) 453-4338; (www.quidel.com)
Auditors: Arthur Andersen LLP, San Diego
Information was compiled from the company’s annual and proxy reports.
